UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):January 13, 2014
Heat Biologics, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
| |
001-35994 | 26-2844103 |
(Commission File Number) | (IRS Employer Identification No.) |
100 Europa Drive
Chapel Hill, NC 27517
(Address of principal executive offices and zip code)
(919) 240-7133
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| | |
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. – Regulation FD Disclosure
Jeff Wolf, the Chairman, Chief Executive Officer and President of Heat Biologics, Inc. (“Heat”), will be making several investor presentations over the next few weeks, including and beginning with a presentation on Tuesday, January 14, 2014 at the 6th Annual Biotech Showcase investor and partnering conference held at the Parc 55 Wyndham - Union Square, San Francisco, California. In connection with that presentation, Mr. Wolf intends to discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein by reference.
The slide presentation attached as Exhibit 99.1 to this Report includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking” rather than historical.
The information included in this Item 7.01 and in Exhibits 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
The following exhibit is being filed as part of this Report.
| | |
Exhibit Number | | Description |
| | |
99.1 | | Presentation materials to be provided at the Heat Biologics, Inc. investor presentations. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
Dated: January 13, 2014 | HEAT BIOLOGICS, INC. |
| (Registrant) |
| | |
| By: | /s/ Jeff Wolf |
| Name: | Jeff Wolf |
| Title: | Chairman, President and Chief Executive Officer |
EXHIBIT INDEX
| | |
Exhibit Number | | Description |
| | |
99.1 | | Presentation materials to be provided at the Heat Biologics, Inc. investor presentations. |
